Why Are Investors Cheering Cardiff Oncology's New Data In Colorectal Cancer Setting?Benzinga • 09/09/21
Cardiff Oncology Announces New Data from Phase 1b/2 Trial in KRAS-mutated Metastatic Colorectal Cancer Showing Robust Objective Response Rate and Progression Free SurvivalPRNewsWire • 09/08/21
Cardiff Oncology to Present New Data from Lead Clinical Program in KRAS-mutated Metastatic Colorectal Cancer on September 8, 2021PRNewsWire • 08/25/21
Cardiff Oncology Reports Second Quarter 2021 Results and Provides Business UpdatesPRNewsWire • 08/05/21
Cardiff Oncology (CRDF) May Report Negative Earnings: Know the Trend Ahead of Q2 ReleaseZacks Investment Research • 08/03/21
Cardiff Oncology to Participate in a Fireside Chat at the William Blair Biotech Focus Conference 2021PRNewsWire • 07/06/21
Cardiff Oncology Announces the Appointment of Two New Independent Members to its Board of DirectorsPRNewsWire • 06/10/21
Cardiff Oncology Announces First Patient Dosed in a Phase 2 Trial of Onvansertib in Combination with Irinotecan and 5-FU in Pancreatic CancerPRNewsWire • 06/08/21
Are Options Traders Betting on a Big Move in Cardiff Oncology (CRDF) Stock?Zacks Investment Research • 05/24/21
Strength Seen in Cardiff Oncology (CRDF): Can Its 10.3% Jump Turn into More Strength?Zacks Investment Research • 05/06/21
Cardiff Oncology's Onvansertib Shows Durable Response, Progression-Free Survival In Colorectal Cancer PatientsBenzinga • 04/12/21
Cardiff Oncology Announces Onvansertib Phase 1b/2 Data that Continues to Demonstrate Robust Response to Treatment and Progression-Free Survival in KRAS-Mutated mCRCPRNewsWire • 04/12/21
Cardiff Oncology Presents Findings from its Expanded Access Program Highlighting the Clinical Benefit of Onvansertib in Heavily Pretreated Patients with Metastatic KRAS-Mutated mCRCPRNewsWire • 04/10/21
Cardiff Oncology in Collaboration with MIT Presents Gene Signature Analyses Data Identifying Androgen-Independent Mechanism for Onvansertib-Abiraterone Synergy in mCRPCPRNewsWire • 04/10/21
Cardiff Oncology to Host Key Opinion Leader Webinar on Onvansertib for the Treatment of KRAS-Mutated Metastatic Colorectal CancerPRNewsWire • 04/08/21